$8.35
3.09% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US15870P3073
Symbol
CSBR
Sector
Industry

Champions Oncology, Inc. Stock price

$8.35
+4.04 93.74% 1M
+3.30 65.35% 6M
+2.73 48.58% YTD
+3.06 57.70% 1Y
+0.45 5.70% 3Y
+0.64 8.30% 5Y
+2.71 48.05% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.25 3.09%
ISIN
US15870P3073
Symbol
CSBR
Sector
Industry

Key metrics

Market capitalization $115.39m
Enterprise Value $119.71m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.23
P/S ratio (TTM) P/S ratio 2.15
P/B ratio (TTM) P/B ratio 167.97
Revenue growth (TTM) Revenue growth 7.19%
Revenue (TTM) Revenue $53.57m
EBIT (operating result TTM) EBIT $-352.00k
Free Cash Flow (TTM) Free Cash Flow $-2.82m
Cash position $2.75m
EPS (TTM) EPS $-0.05
P/S forward 2.06
EV/Sales forward 2.13
Short interest 3.96%
Show more

Is Champions Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Champions Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Champions Oncology, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Champions Oncology, Inc.:

Buy
100%

Financial data from Champions Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Oct '24
+/-
%
54 54
7% 7%
100%
- Direct Costs 30 30
1% 1%
55%
24 24
16% 16%
45%
- Selling and Administrative Expenses 15 15
4% 4%
28%
- Research and Development Expense 7.38 7.38
35% 35%
14%
1.72 1.72
128% 128%
3%
- Depreciation and Amortization 2.08 2.08
17% 17%
4%
EBIT (Operating Income) EBIT -0.35 -0.35
96% 96%
-1%
Net Profit -0.60 -0.60
94% 94%
-1%

In millions USD.

Don't miss a Thing! We will send you all news about Champions Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Champions Oncology, Inc. Stock News

Neutral
Seeking Alpha
one day ago
Champoins Oncology broke out of a multiyear downtrend following its Q2'25 earnings. Management has embarked on a one-way journey to reduce working capital and grow the business with zero incremental capital. This has succeeded and the business is now in a prime position to grow sales at 10% CAGR to CY'26 in my opinion.
Neutral
Seeking Alpha
17 days ago
Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2024 Earnings Conference Call December 11, 2024 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Operator Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2025 Earnings Call.
Neutral
Accesswire
17 days ago
HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024. Second Quarter and Recent Highlights: Total revenue increased 17% to $13.5 million Gross profit of $6....
More Champions Oncology, Inc. News

Company Profile

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Head office United States
CEO Ronnie Morris
Employees 210
Founded 1985
Website www.championsoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today